Macrocyclic Indole Compounds Inhibiting HCV Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infections are inadequate, and there is a need for effective inhibitors of HCV RNA polymerase to address this gap.
Innovation Solution
Development of macrocyclic indole compounds, specifically compounds of formula (I) and their pharmaceutically acceptable salts, which are designed to inhibit HCV polymerase and are used in pharmaceutical compositions for treating or preventing HCV infections, involving aromatic rings with specific substituents and functional groups that form a macrocyclic structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HCV infections are used, then existing therapeutic options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent employs parameter changes by systematically varying structural parameters of indole compounds (substituents at different positions, ring modifications, macrocyclic variations) to optimize HCV polymerase inhibition. This is evident in the extensive definition of possible substituents (Q1, Q2, R1-R23) and ring structures (A, Het, Ar) that can be modified to improve therapeutic effectiveness while maintaining the core indole framework.
2Reliability
If macrocyclic indole compounds with complex structures are developed, then inhibitory activity against HCV polymerase is achieved, but structural complexity increases
Solution Approach 1:
The macrocyclic indole compounds are segmented into distinct functional modules: a core indole structure (positions 1-7), substituent groups (Q1, Q2, R1-R23), and macrocyclic linkers (A, Het, Ar). This segmentation allows systematic optimization of each module's contribution to HCV polymerase inhibition while managing overall molecular complexity through modular design.
Solution Approach 2:
The patent designs macrocyclic indole compounds with multiple functional groups that can simultaneously interact with different regions of the HCV polymerase active site. The substituents Q1 and Q2, along with various R groups, provide multi-functionality by enabling hydrogen bonding, hydrophobic interactions, and steric complementarity, allowing a single compound to achieve high inhibitory activity through multiple binding mechanisms.
Data Source
AI summary
Compounds of the formula (I):wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.